Financial Instruments And Risk Management (Tables)

3 Months Ended

Mar. 31, 2012

Financial Instruments And Risk Management [Abstract]

Derivatives Designated As Hedging Instruments Fair Values Of Derivative Instruments

	Asset Derivatives
	March 31, 2012			December 31, 2011
(In thousands)	Balance Sheet Location	Fair Value		Balance Sheet Location	Fair Value
Interest rate swaps	Prepaid expenses and other current assets	$	38,598	Prepaid expenses and other current assets	$	29,773
Total		$	38,598		$	29,773

	Liability Derivatives
	March 31, 2012			December 31, 2011
(In thousands)	Balance Sheet Location	Fair Value		Balance Sheet Location	Fair Value
Interest rate swaps	Other current liabilities	$	2,756	Other current liabilities	$	658
Foreign currency forward contracts	Other current liabilities		31,572	Other current liabilities		57,075
Total		$	34,328		$	57,733

Derivatives Not Designated As Hedging Instruments Fair Values Of Derivative Instruments

	Asset Derivatives
	March 31, 2012			December 31, 2011
(In thousands)	Balance Sheet Location	Fair Value		Balance Sheet Location	Fair Value
Foreign currency forward contracts	Prepaid expenses and other current assets	$	7,129	Prepaid expenses and other current assets	$	3,802
Purchased cash convertible note hedge	Other assets		511,600	Other assets		460,000
Total		$	518,729		$	463,802

	Liability Derivatives
	March 31, 2012			December 31, 2011
(In thousands)	Balance Sheet Location	Fair Value		Balance Sheet Location	Fair Value
Foreign currency forward contracts	Other current liabilities	$	6,431	Other current liabilities	$	11,760
Cash conversion feature of Cash Convertible Notes	Long-term debt		511,600	Long-term debt		460,000
Total		$	518,031		$	471,760

Effect Of Derivative Instruments On The Condensed Consolidated Statements Of Operations Derivatives In Fair Value Hedging Relationships

	Location of Gain or (Loss) Recognized in Earnings on Derivatives	Amount of Gain or (Loss) Recognized in Earnings on Derivatives
(In thousands)		Three Months Ended March 31,
		2012		2011
Interest Rate Swaps	Interest Expense	$	11,896	$	(6,328	)
Total		$	11,896	$	(6,328	)

	Location of Gain or (Loss) Recognized in Earnings on Hedged Items	Amount of Gain or (Loss) Recognized in Earnings on Hedging Items
(In thousands)		Three Months Ended March 31,
		2012			2011
2018 Senior Notes	Interest Expense	$	(8,825	)	$	6,328
Total		$	(8,825	)	$	6,328

Effect Of Derivative Instruments On The Condensed Consolidated Statements Of Operations Derivatives In Cash Flow Hedging Relationships

	Amount of Gain or (Loss) Recognized in AOCE (Net of Tax) on Derivative (Effective Portion)
	Three Months Ended March 31,
(In thousands)	2012			2011
Foreign currency forward contracts	$	11,461		$	1,388
Interest rate swaps		(1,324	)		2,321
Total	$	10,137		$	3,709

	Location of Gain or (Loss) Reclassified from AOCE into Earnings (Effective Portion)	Amount of Gain or (Loss) Reclassified from AOCE into Earnings (Effective Portion)
		Three Months Ended March 31,
(In thousands)		2012			2011
Foreign currency forward contracts	Net revenues	$	(5,255	)	$	745
Interest rate swaps	Interest expense		(374	)		(1,782	)
Total		$	(5,629	)	$	(1,037	)

	Location of Gain Excluded from the Assessment of Hedge Effectiveness	Amount of Gain Excluded from the Assessment of Hedge Effectiveness
		Three Months Ended March 31,
(In thousands)		2012		2011
Foreign currency forward contracts	Other (expense) income, net	$	5,711	$	34
Total		$	5,711	$	34

Effect Of Derivative Instruments On The Condensed Consolidated Statements Of Operations Derivatives In Net Investment Hedging Relationships

	Amount of Gain or (Loss) Recognized in AOCE (Net of Tax) on Derivative (Effective Portion)
	Three Months Ended March 31,
(In thousands)	2012		2011
Foreign currency borrowings	$	—	$	(33,718	)
Total	$	—	$	(33,718	)

Effect Of Derivative Instruments On The Condensed Consolidated Statements Of Operations Derivatives Not Designated As Hedging Instruments

	Location of Gain or (Loss) Recognized in Earnings on Derivatives	Amount of Gain or (Loss) Recognized in Earnings on Derivatives
		Three Months Ended March 31,
(In thousands)		2012			2011
Foreign currency forward contracts	Other (expense) income, net	$	5,255		$	11,462
Cash conversion feature of Cash Convertible Notes	Other (expense) income, net		(51,600	)		(49,300	)
Purchased cash convertible note hedge	Other (expense) income, net		51,600			49,300
Total		$	5,255		$	11,462

Financial Assets And Liabilities Carried At Fair Value

	March 31, 2012
(In thousands)	Level 1		Level 2		Level 3		Total
Financial Assets:
Cash equivalents:
Money market funds	$	60,676	$	—	$	—	$	60,676
Total cash equivalents		60,676		—		—		60,676
Trading securities:
Equity securities — exchange traded funds		7,218		—		—		7,218
Total trading securities		7,218		—		—		7,218
Available-for-sale fixed income investments:
U.S. Treasuries		—		12,193		—		12,193
Corporate bonds		—		7,630		—		7,630
Agency mortgage-backed securities		—		1,395		—		1,395
Other		—		2,543		—		2,543
Total available-for-sale fixed income investments		—		23,761		—		23,761
Available-for-sale equity securities:
Biosciences industry		62		—		—		62
Total available-for-sale equity securities		62		—		—		62
Foreign exchange derivative assets		—		7,129		—		7,129
Interest rate swap derivative assets		—		38,598		—		38,598
Purchased cash convertible note hedge		—		511,600		—		511,600
Total assets at fair value (1)	$	67,956	$	581,088	$	—	$	649,044
Financial Liabilities:
Foreign exchange derivative liabilities	$	—	$	38,003	$	—	$	38,003
Interest rate swap derivative liabilities		—		2,756		—		2,756
Cash conversion feature of Cash Convertible Notes		—		511,600		—		511,600
Contingent consideration		—		—		383,751		383,751
Total liabilities at fair value (1)	$	—	$	552,359	$	383,751	$	936,110

	December 31, 2011
(In thousands)	Level 1		Level 2		Level 3		Total
Financial Assets:
Cash equivalents:
Money market funds	$	152,331	$	—	$	—	$	152,331
Total cash equivalents		152,331		—		—		152,331
Trading securities:
Equity securities — exchange traded funds		6,760		—		—		6,760
Total trading securities		6,760		—		—		6,760
Available-for-sale fixed income investments:
U.S. Treasuries		—		1,519		—		1,519
Corporate bonds		—		7,192		—		7,192
Agency mortgage-backed securities		—		12,346		—		12,346
Other		—		2,697		—		2,697
Total available-for-sale fixed income investments		—		23,754		—		23,754
Available-for-sale equity securities:
Biosciences industry		172		—		—		172
Total available-for-sale equity securities		172		—		—		172
Foreign exchange derivative assets		—		3,802		—		3,802
Interest rate swap derivative assets		—		29,773		—		29,773
Purchased cash convertible note hedge		—		460,000		—		460,000
Total assets at fair value (1)	$	159,263	$	517,329	$	—	$	676,592
Financial Liabilities:
Foreign exchange derivative liabilities	$	—	$	68,835	$	—	$	68,835
Interest rate swap derivative liabilities		—		658		—		658
Cash conversion feature of Cash Convertible Notes		—		460,000		—		460,000
Contingent consideration		—		—		376,110		376,110
Total liabilities at fair value (1)	$	—	$	529,493	$	376,110	$	905,603

⁽¹⁾  The Company chose not to elect the fair value option for its financial assets and liabilities that had not been previously carried at fair value. Therefore, material financial assets and liabilities not carried at fair value, such as short-term and long-term debt obligations and trade accounts receivable and payable, are still reported at their carrying values.